Undifferentiated Carcinoma — Trials

Undifferentiated Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

162 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 15
Ph III recruiting: 3
Growth YoY: —
Industry share: 4%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (30)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06814496	Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT)	recruiting	Phase 1 / Phase 2	30	University of ArizonaOTHER	1	Sep 22, 2026	clinicaltrials
NCT06902376	XL092 and Cemiplimab in BRAF WT Thyroid Cancer(NEO-COMBATXL)	recruiting	Phase 1	12	UNC Lineberger Comprehensive Cancer CenterOTHER	1	Sep 8, 2026